SRRK Scholar Rock Holding Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1727196 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.0%
TTM EPS YoY-2.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-71,732.3%
Net margin-72,563.2%
FCF margin-54,370.7%
EBITDA margin-71,501.6%
Returns
ROE-200.0%
ROA-96.4%
ROIC (approx.)-1,144.3%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets62.2%
Debt / equity1.16x
Current ratio5.41x
Interest coverage-29.23x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-24.2%
Payout ratio—
Capex / revenue35.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | — | — | $33.19M | $18.82M |
| R&D expense | $208.44M | $184.55M | $121.90M | $124.44M | $108.47M |
| SG&A expense | $176.21M | $67.50M | $49.40M | $43.12M | $40.27M |
| Operating income | -$384.64M | -$252.05M | -$171.29M | -$134.37M | -$129.92M |
| Interest expense | $6.89M | $6.84M | $6.50M | $4.70M | $2.10M |
| Pretax income | -$377.73M | -$246.29M | — | — | — |
| Net income | -$377.94M | -$246.29M | -$165.79M | -$134.50M | -$131.80M |
| EBITDA | -$382.99M | -$250.12M | -$168.45M | -$131.38M | -$127.29M |
| EPS (basic) | -3.29 | -2.47 | -1.99 | -2.26 | -3.59 |
| EPS (diluted) | -3.29 | -2.47 | -1.99 | -2.26 | -3.59 |
| Weighted avg. shares (diluted) | 114.70M | 99.84M | 83.35M | 59.61M | 36.71M |
| Balance sheet | |||||
| Cash & equivalents | $323.53M | $180.28M | $104.26M | $105.77M | $215.33M |
| Short-term investments | $44.04M | $259.40M | $178.08M | $212.09M | $40.16M |
| Receivables | $0 | — | — | — | — |
| Inventory | $0 | — | — | — | — |
| Current assets | $385.15M | $451.17M | $288.19M | $328.02M | $265.32M |
| PP&E, net | $1.71M | $2.76M | $4.60M | $7.38M | $9.56M |
| Total assets | $404.27M | $474.92M | $311.04M | $358.17M | $304.44M |
| Current liabilities | $55.42M | $46.94M | $32.74M | $36.39M | $64.30M |
| Short-term debt | — | — | $1.33M | — | $1.58M |
| Long-term debt | $99.71M | $50.15M | $48.68M | $49.74M | $48.42M |
| Total debt | $99.71M | $50.15M | $50.02M | $49.74M | $50.00M |
| Total liabilities | $158.78M | $106.29M | $85.82M | $97.93M | $132.37M |
| Shareholders' equity | $245.49M | $368.63M | $225.22M | $260.24M | $172.07M |
| Net debt | -$223.82M | -$130.14M | -$54.24M | -$56.03M | -$165.33M |
| Shares outstanding | 108.46M | 93.82M | 75.98M | 51.67M | 35.21M |
| Cash flow statement | |||||
| Operating cash flow | -$300.04M | -$200.95M | -$145.23M | -$132.69M | -$126.79M |
| Capital expenditure | $602,000 | $98,000 | $71,000 | $1.06M | $5.25M |
| Free cash flow | -$300.64M | -$201.05M | -$145.30M | -$133.76M | -$132.04M |
| Investing cash flow | $218.69M | -$76.06M | $41.14M | -$171.70M | $134.31M |
| Financing cash flow | $228.40M | $353.03M | $102.57M | $194.83M | $44.95M |
| Depreciation & amortization | $1.66M | $1.94M | $2.84M | $2.99M | $2.63M |
| Stock-based compensation | $75.60M | $36.63M | $27.14M | $27.70M | $23.15M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.